Everid Medicines (Beijing) Limited

Phase 1: Comprehensively evaluate the safety, efficacy and pharmacokinetic characteristics of two different dosing doses and frequencies of elacycline in CABP subjects, and comprehensively evaluate and determine the dosing dose and frequency of the elacycline group in Phase 2 based on the above results. Phase 2: Primary purpose: To evaluate the clinical efficacy of elacycline and moxifloxacin in the mITT population at the TOC visit Secondary purpose: To evaluate the clinical efficacy of elacycline group and moxifloxacin group i. Clinical efficacy of ITT and CE populations at the TOC visit ii. Early clinical response (ECR) of ITT and mITT populations iii. Clinical efficacy of ITT, mITT and CE populations at the EOT visit iv. Microbiological efficacy and comprehensive efficacy of m-mITT and ME populations at the EOT and TOC visits v. Safety and tolerability in the safety analysis population Exploratory purpose: To evaluate the all-cause mortality rate in the mITT and CE populations of elacycline group and moxifloxacin group within 28 days after the first dose.

1. To evaluate the pharmacokinetics of single and multiple intravenous (IV) infusions of cefepime/VNRX-5133 in healthy Chinese subjects. 2. To evaluate the safety and tolerability of single and multiple intravenous infusions of cefepime/VNRX-5133 in healthy Chinese subjects.

To evaluate the efficacy (microbiological clearance and symptom resolution) and safety of cefepime/VNRX-5133 compared with meropenem for the treatment of complicated urinary tract infections (including acute pyelonephritis).